p53 expression in fallopian tube carcinomas

Cancer Letters

Volumn 156, Issue 1, 2000, Pages 1-7

  Rosen, A C ^a   Ausch, C ^a   Klein, M ^b   Graf, A H ^c   Metzenbauer, M ^a   Philipp, K ^a   Reiner, A ^a  

^a DANUBE HOSPITAL   (Austria)

^b HANUSCH HOSPITAL   (Austria)

^c St Johanns Spital   (Austria)

Author keywords

p53 expression; Primary fallopian tube carcinoma; Survival analysis

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE TUBE CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

FALLOPIA;

EID: 0034256961     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(00)00335-9     Document Type: Article

References (25)

1. Dodson M.G., Ford J.H., Averette H.E. Clinical aspects of fallopian tube carcinoma. Obstet. Gynecol. 36:1970;935-939.
2. Hanton E.M., Malkasian G.D., Dahlin D.C., Pratt J. Primary carcinoma of the fallopian tube. Am. J. Obstet. Gynecol. 59:1966;832-939.
3. Denham J.W., MacLennan K.A. The management of primary carcinoma of the fallopian tube: experiences with 40 patients. Cancer. 53:1984;166-172.
4. Pfeiffer P., Mogensen H., Amtrup F., Honore E. Primary carcinoma of the fallopian tube. Acta Oncol. 28:1989;7-11.
5. Rosen A.C., Graf A.H., Klein M. ploidy in primary fallopian tube carcinoma using image cytrometry. Int. J. Cancer. 58:1994;362-365.
6. Rosen A.C., Ausch C., Hafner E., Klein M., Lahousen M., Graf A.H., Reiner A. Austrian Cooperative Study Group For Fallopian Tube Carcinoma, A 15-year overview of management and prognosis in primary fallopian tube carcinoma. Eur. J. Cancer. 34:1998;1725-1729.
7. McMurray E.H., Jacobs A.J., Perez C.A., Camel H.M., Kao M.S., Galakatos A. Carcinoma of the fallopian tube. Cancer. 58:1986;2070-2075.
8. Lacy M.Q., Hartmann L.C., Keeney G.L., Cha S.C., Wieand H.S., Podratz K.C., Roche P.C. C-Erb-2 and P53 expression in fallopian tube carcinoma. Cancer. 75:1995;2891-2896.
9. Runnebaum I.B., Tong X.W., Möbus V.J., Kieback D.G., Rosenthal H.E., Kreienberg R. Mutant His175 identified in a newly established fallopian tube carcinoma cell line secreting interleukin 6. FEBS Lett. 353:1994;29-32.
10. Runnebaum I.B., Köhler T., Stickeler E., Rosenthal H.E., Kieback D.G., Kreienberg R. mutation is associated with high s-phase fraction in primary fallopian tube adenocarcinoma. Br. J. Cancer. 74:1996;1157-1160.
11. Di Saia P.J., Creasman W.T. Carcinoma of the fallopian tube. Achenbach F. Clinical Gynecology Oncology. 1997;375-381 Mosby, St. Louis, MO.
12. Hu C.Y., Taymor M.L., Hertig A.T. Primary carcinoma of the fallopian tube. Am. J. Obstet. Gynecol. 59:1950;58-67.
13. Kaplan E.L., Meier P. Non-parametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481.
14. Mantel N. Evaluation of survival data and two new rank order statistics arising in 1st considerations. Cancer Chemother. Rep. 50:1986;163-170.
15. Cox D.R. Regression models and life tables. J. R. Stat. Soc. B. 34:1972;187-220.
16. Benedet J.L., White W. Malignant tumors of fallopian tube. Coppelson M. Gynecologic Oncology. 1981;621-629 Churchill Livingstone, Melbourne.
17. Finlay C.A., Hinds P.W., Tan T.W., Eliyahu D., Oren E.M., Levine A.J. Activating mutations for transformation by p53 produce a gene product that forms an Hsc70-P53 complex with an altered half life. Mol. Cell. Biol. 8:1988;531-539.
18. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:1994;4855-4878.
19. Hall P.A., Lane D.P. In tumor pathology: can we trust immunohistochemistry? Revisited, J. Pathol. 172:1994;1.
20. Pereira H., Silva S., Juliao R., Garcia P., Perpetua F. Prognostic markers for colorectal cancer: expression of p53 and BCL2. World. J. Surg. 21:1997;210-213.
21. Soussi T., Legtos Y., Lubiu R., Schlichtholz B. multifactorial analysis of p53 alteration in human cancer: a review. Int. J. Cancer. 57:1994;1.
22. Marks J.R., Davidoff A.M., Kerns B.J., Humphrey P.A., Pence J.C., Dodge R.K., Burchuck A. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res. 51:1991;2979-2984.
23. Vogelstein B., Fearon R.R., Hamilton S.R., Kern S.E., Preisinger A.C., Lepeprt M., Nacamura V., White R., Smits A.M., Bos J.L. Genetic alterations during colorectal tumor development. N. Engl. J. Med. 319:1998;525.
24. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorgenesis. Cell. 61:1990;759.
25. Zheng W., Sung J., Cao P., Zhang Z.F., Cai R., Godwin T.A., Kramer E.E., Lauchlan S.C. Early occurrence and prognostic significance of p53 alteration in primary carcinoma of the fallopian tube. Gynecol. Oncol. 64:1997;38-48.